LIKE THE PHARMA industry market dynamics, this is akin to an innovator brand drug loosing the patent and opening the gate for cheaper generics. The Myriad court decision triggered the emergence of cheaper competitive tests.
LIKE THE PHARMA industry market dynamics, this is akin to an innovator brand drug loosing the patent and opening the gate for cheaper generics. The Myriad court decision triggered the emergence of cheaper competitive tests.